Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The FDA also recommends that prescribed users reduce their caloric intake and increase their exercise The weight loss drug ...
Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback